ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Betta Pharmaceuticals and Genmab side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Betta PharmaceuticalsGenmab
studies on the registry10077
open to participants now2115
phase 3 studies under way417
reach primary completion within a year69
programswith a study of their own in two years59

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBetta PharmaceuticalsGenmab
Phase 100%

Genmab: 4 of its 9 programs at phase 1

  1. Anti-SLITRK6 Antibody-drug Conjugate GEN1106phase 1
  2. Bispecific Antibody GEN1079phase 1
  3. GEN1119phase 1
  4. GEN3018phase 1
44%
Phase 2

Betta Pharmaceuticals: 2 of its 5 programs at phase 2

  1. pamvatamigphase 2
  2. BPI-572270phase 2
40%

Genmab: 1 of its 9 programs at phase 2

  1. GEN1078phase 2
11%
Phase 3

Betta Pharmaceuticals: 3 of its 5 programs at phase 3

  1. ensartinibphase 3
  2. befotertinibphase 3
  3. vorolanibphase 3
60%

Genmab: 4 of its 9 programs at phase 3

  1. epcoritamabphase 3
  2. rinatabart sesutecanphase 3
  3. petosemtamabphase 3
  4. acasunlimabphase 3
44%
Approved, new studies00%00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Betta Pharmaceuticals1 readouts · 0 phase 3·······

Betta Pharmaceuticals, Jun ’27: 1 program whose next study reaches primary completion

  1. vorolanibphase 3 · Jun 0 · NCT07809802
····
Genmab3 readouts · 2 phase 3····

Genmab, Mar ’27: 1 program whose next study reaches primary completion

  1. epcoritamabphase 3 · Mar 0 · NCT05451810
···

Genmab, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. acasunlimabphase 3 · Jul 30 · NCT06635824
·

Genmab, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. rinatabart sesutecanphase 3 · Sep 0 · NCT07604766
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Betta Pharmaceuticals

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Genmab

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionBetta PharmaceuticalsGenmab
Carcinoma, Non-Small-Cell Lungboth · compare here

Betta Pharmaceuticals in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. ensartinibphase 3
  2. befotertinibphase 3
  3. pamvatamigphase 2
  4. BPI-572270phase 2

Their studies: Betta Pharmaceuticals’ studies of Carcinoma, Non-Small-Cell Lung in search

Genmab in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. rinatabart sesutecanphase 3
  2. acasunlimabphase 3

Their studies: Genmab’s studies of Carcinoma, Non-Small-Cell Lung in search

Lung Neoplasmsboth · compare here

Betta Pharmaceuticals in Lung Neoplasms: 1 program

  1. ensartinibphase 3

Their studies: Betta Pharmaceuticals’ studies of Lung Neoplasms in search

Genmab in Lung Neoplasms: 2 programs

  1. petosemtamabphase 3
  2. acasunlimabphase 3

Their studies: Genmab’s studies of Lung Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetBetta PharmaceuticalsGenmab
EGFRbefotertinibrule, pamvatamigrulepetosemtamabrule
A target, or a pathogen for a vaccine, known for: Betta Pharmaceuticals 4 of 5 · Genmab 5 of 9 programs (9 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.